Dr Vieta Replies

Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: The letter by Dr Mayo-Wilson expresses concern about potential discrepancies between an internal company report and the article that we published on the effectiveness of adjunctive gabapentin in bipolar disorder. Discrepancies might result in publication bias, so I would like to provide further details on the study.Ours was an investigator-initiated trial that was originally sponsored by Parke-Davis Spain (which had been bought by Pfizer at the time of publication).